Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NALBUPHINE vs FINASTERIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mixed opioid agonist-antagonist; agonist at κ-opioid receptors and antagonist/partial agonist at μ-opioid receptors.
Finasteride is a competitive 5-alpha-reductase inhibitor that prevents conversion of testosterone to dihydrotestosterone (DHT), thereby reducing DHT levels in serum and prostate tissue.
Moderate to severe pain,Supplement to balanced anesthesia,Preoperative and postoperative analgesia,Obstetrical analgesia during labor and delivery
Benign prostatic hyperplasia (BPH),Male pattern baldness (androgenetic alopecia)
10-20 mg IV/IM/SC every 3-6 hours as needed for pain; maximum single dose 20 mg, maximum total daily dose 160 mg.
1 mg orally once daily for androgenetic alopecia; 5 mg orally once daily for benign prostatic hyperplasia.
Terminal elimination half-life is 5 hours; clinically, in hepatic impairment or elderly, half-life may be prolonged up to 8-10 hours.
Terminal elimination half-life is approximately 6-8 hours (range 4-12 hours) in young adults; prolonged to ~8 hours in elderly due to reduced clearance; clinical effect on DHT suppression persists for 24 hours post-dose.
Hepatic metabolism primarily via glucuronidation and oxidative pathways; minor involvement of CYP450 enzymes.
Metabolized primarily via CYP3A4 in the liver; two inactive metabolites (t-butyl side chain oxidation and glucuronide conjugate).
Primarily hepatic metabolism; <5% excreted unchanged in urine; about 70% excreted in feces via biliary elimination.
Renal (39% as metabolites, <0.1% as unchanged drug); fecal (57% as metabolites); biliary elimination contributes to fecal route.
Approximately 50% bound to plasma proteins, primarily albumin.
Approximately 93% bound to plasma proteins (primarily albumin and to a lesser extent alpha-1-acid glycoprotein).
2.3 L/kg; indicates extensive tissue distribution, consistent with moderate lipophilicity.
Volume of distribution = 76 L (approximately 1.0-1.1 L/kg), indicating extensive tissue distribution; crosses blood-brain barrier and partitions into seminal fluid.
Intravenous: 100%; Intramuscular: approximately 80%; Oral: negligible (<20%) due to extensive first-pass metabolism.
Oral bioavailability is approximately 63% (range 50-80%) due to incomplete absorption and first-pass metabolism; food does not significantly affect bioavailability.
Cr Cl 30-50 m L/min: administer 75% of normal dose every 6 hours; Cr Cl <30 m L/min: administer 50% of normal dose every 8 hours.
No dose adjustment required for any level of renal impairment including end-stage renal disease.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50% or use alternative.
No formal studies in hepatic impairment. Caution advised; use not recommended in severe hepatic impairment due to potential accumulation. No specific Child-Pugh based dose recommendations.
0.1-0.2 mg/kg IV/IM/SC every 3-6 hours as needed; maximum single dose 20 mg.
Not indicated in pediatric patients. Safety and efficacy not established. Avoid use in children.
Initiate at 50% of adult dose (5-10 mg) and titrate cautiously due to increased sensitivity and risk of respiratory depression.
No age-related dose adjustment necessary. Monitor for adverse effects (e.g., sexual dysfunction, mood changes) due to potential increased sensitivity.
Risk of respiratory depression, particularly in opioid-naive patients; risk of dependence and abuse; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death.
No FDA black box warning.
Respiratory depression may occur, especially in elderly, cachectic, or debilitated patients,Avoid use in patients with head injury or increased intracranial pressure,May precipitate withdrawal in opioid-dependent patients,Hypotension, biliary tract spasm, and seizure risk
Risk of high-grade prostate cancer (decreased PSA levels may mask detection),Sexual adverse effects (e.g., decreased libido, erectile dysfunction, ejaculatory disorder) may persist after discontinuation,Increased risk of mood disturbances including depression and suicidal ideation,Not indicated for use in women or children; avoid handling crushed tablets during pregnancy due to risk to male fetus
Hypersensitivity to nalbuphine or any component,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting,Suspected or known gastrointestinal obstruction
Pregnancy (category X; risk of hypospadias in male fetuses),Known hypersensitivity to finasteride or any component of the formulation
No significant food-drug interactions. Avoid alcohol and grapefruit juice as they may enhance CNS depression.
No significant food interactions reported; finasteride may be taken with or without food. Avoid excessive alcohol consumption as it may worsen BPH symptoms or liver function.
FDA Category C. First trimester: Limited human data, no evidence of major malformations in animal studies at 4-6x MRHD. Second/third trimester: Chronic use may cause neonatal opioid withdrawal syndrome (NOWS) including irritability, hypertonia, tremors, poor feeding. Use only if benefit outweighs risk.
Contraindicated in pregnancy. Finasteride inhibits conversion of testosterone to dihydrotestosterone, which is critical for male fetal external genitalia development. Risk of hypospadias and other urogenital malformations if exposed in utero, particularly during first trimester. Pregnancy category X.
Excreted in human milk in low concentrations (M/P ratio ~0.6). Relative infant dose estimated 0.5-1% of maternal weight-adjusted dose. Monitor infant for sedation and poor feeding. American Academy of Pediatrics considers compatible with breastfeeding with caution.
Not recommended. Finasteride is excreted in human milk; M/P ratio not reported. Risk to nursing infant unknown, but potential for adverse effects on male infant genitalia. Use contraindicated during breastfeeding.
No specific dose adjustments recommended for pregnancy. Increased clearance and volume of distribution in third trimester may potentially reduce efficacy; titrate to effect. Avoid in prolonged labor due to risk of fetal bradycardia.
No dose adjustments applicable as finasteride is contraindicated in pregnancy. No pharmacokinetic studies in pregnant women due to ethical concerns.
Nalbuphine is a mixed agonist-antagonist opioid with a ceiling effect for respiratory depression, making it safer than pure agonists. It can precipitate withdrawal in opioid-dependent patients. Monitor for sedation and hypotension. Reversal with naloxone may be less effective. Use with caution in hepatic impairment. Not recommended for chronic pain due to psychotomimetic effects.
Finasteride inhibits 5α-reductase type II, reducing conversion of testosterone to DHT. Onset of effect in benign prostatic hyperplasia (BPH) requires 6-12 months; for androgenetic alopecia, 3-6 months. Serum PSA levels decrease by approximately 50% after 6 months; multiply PSA by 2 when interpreting. Avoid handling crushed or broken tablets if pregnant or planning to become pregnant due to risk of fetal genital abnormalities. Use with caution in hepatic impairment; contraindicated in women of childbearing potential, children, and patients with hypersensitivity to 5α-reductase inhibitors.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, sleep aids) as they can increase dizziness and drowsiness.,Do not drive or operate heavy machinery until you know how nalbuphine affects you.,Report any signs of withdrawal (e.g., restlessness, tearing, runny nose, yawning, sweating) if you have been taking other opioids.,Seek emergency care if you experience trouble breathing, severe dizziness, or hallucinations.,Do not stop abruptly; tapering may be needed to avoid withdrawal symptoms.
Take finasteride exactly as prescribed, once daily with or without food.,It may take 3-6 months for hair regrowth or improvement in urinary symptoms; continue therapy as directed even if no immediate benefit is noted.,Report any breast tenderness, enlargement, or lumps; also report any new onset of sexual dysfunction (e.g., decreased libido, erectile dysfunction, ejaculation disorder).,Do not donate blood while taking finasteride and for at least 1 month after stopping, to prevent exposure to a pregnant female.,Women who are pregnant or may become pregnant should not handle crushed or broken tablets due to risk of harm to male fetus.,Serum PSA levels will decrease; inform your healthcare provider that you take finasteride before any PSA test.,Store at room temperature (20-25°C) in a dry place, away from light and moisture.
"The combination of trifluoperazine, a phenothiazine antipsychotic, with nalbuphine, a mixed opioid agonist-antagonist, can lead to additive central nervous system (CNS) depression, including increased sedation, respiratory depression, and hypotension. Trifluoperazine may enhance the depressant effects of nalbuphine on the brainstem respiratory centers and vasomotor centers. Clinically, this interaction may result in excessive sedation, respiratory compromise, and orthostatic hypotension, particularly in elderly or debilitated patients."
"Combined use of nalbuphine, a mixed opioid agonist-antagonist, with entacapone, a catechol-O-methyltransferase (COMT) inhibitor, may increase the risk of opioid-related adverse effects, including respiratory depression and sedation, due to additive central nervous system depression. Entacapone can also inhibit the metabolism of catecholamines, potentially exacerbating opioid-induced constipation and urinary retention. Clinically, patients may experience enhanced sedation or respiratory compromise, particularly in elderly or debilitated populations."
"Concomitant use of clozapine and nalbuphine may potentiate central nervous system (CNS) depression, leading to additive sedative and respiratory depressant effects. Both drugs act on the CNS via distinct mechanisms but converge on common pathways, increasing the risk of hypotension, bradycardia, and profound sedation. Clinically, patients may experience excessive drowsiness, confusion, or respiratory compromise, particularly in those with pre-existing comorbidities or concurrent use of other CNS depressants."
"Finasteride, a 5α-reductase inhibitor used for benign prostatic hyperplasia, may inhibit cytochrome P450 3A4 (CYP3A4) isoenzymes. Cyclosporine is primarily metabolized by CYP3A4. Coadministration can lead to reduced cyclosporine clearance, elevated blood concentrations, and increased risk of nephrotoxicity, hypertension, and neurotoxicity."
"Finasteride, a 5α-reductase inhibitor used for benign prostatic hyperplasia, may weakly inhibit CYP3A4, the primary enzyme responsible for sildenafil metabolism. This can lead to a modest reduction in sildenafil clearance, increasing systemic exposure and potentially enhancing both therapeutic effects and adverse events such as headache, flushing, dyspepsia, and hypotension. Clinically, this interaction is generally mild but may require dose adjustment in patients predisposed to sildenafil side effects."
"Finasteride, a 5α-reductase inhibitor, may inhibit CYP3A4-mediated metabolism of netupitant, a neurokinin-1 receptor antagonist primarily metabolized by CYP3A4. This can lead to increased netupitant plasma concentrations, potentially enhancing its adverse effects such as headache, fatigue, or dizziness. Clinically, the combination may require dose adjustment or close monitoring for netupitant toxicity."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NALBUPHINE vs FINASTERIDE, answered by our medical review team.
NALBUPHINE is a Opioid Agonist-Antagonist that works by Mixed opioid agonist-antagonist; agonist at κ-opioid receptors and antagonist/partial agonist at μ-opioid receptors.. FINASTERIDE is a 5-alpha Reductase Inhibitor that works by Finasteride is a competitive 5-alpha-reductase inhibitor that prevents conversion of testosterone to dihydrotestosterone (DHT), thereby reducing DHT levels in serum and prostate tissue.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NALBUPHINE and FINASTERIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NALBUPHINE is: 10-20 mg IV/IM/SC every 3-6 hours as needed for pain; maximum single dose 20 mg, maximum total daily dose 160 mg.. The standard adult dose of FINASTERIDE is: 1 mg orally once daily for androgenetic alopecia; 5 mg orally once daily for benign prostatic hyperplasia.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NALBUPHINE and FINASTERIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NALBUPHINE is classified as Category A/B. FDA Category C. First trimester: Limited human data, no evidence of major malformations in animal studies at 4-6x MRHD. Second/third trimester: Chronic use may cause neonatal opioi. FINASTERIDE is classified as Category D/X. Contraindicated in pregnancy. Finasteride inhibits conversion of testosterone to dihydrotestosterone, which is critical for male fetal external genitalia development. Risk of hypos. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.